Double-Blind, Double-Dummy, Multinational, Multicenter, Parallel-Group Design Clinical Trial of Clinical Non-Inferiority of Formoterol 12 μg/Unit Dose in a b.i.d. Regimen Administered via an HFA-Propellant-pMDI or a Dry Powder Inhaler in a 12-Week Treatment Period of Moderate to Severe Stable Persistent Asthma in Adult Patients

Publisher： Karger

E-ISSN： 1423-0356|72|1|20-27

ISSN： 0025-7931

Source： Respiration, Vol.72, Iss.1, 2005-05, pp. : 20-27

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Randomized, Double-Blind, Double-Dummy, Single-Dose, Crossover Trial Evaluating the Efficacy and Safety Profiles of Two Dose Levels (12 and 24 μg) of Formoterol-HFA (pMDI) vs. Those of a Dose Level (24 μg) of Formoterol-DPI (Foradil®/Aerolizer™) and of Placebo (pMDI or Aerolizer) in Moderate to Severe Asthmatic Patients

By  

Respiration, Vol. 72, Iss. 1, 2005-05 ,pp. : 13-19

Karger

Access to resources Recommend Favorite

A Randomized, Double-Blind, Double-Dummy, Single-Dose, Efficacy Crossover Trial Comparing Formoterol-HFA (pMDI) versus Formoterol-DPI (AerolizerTM) and Placebo (pMDI or AerolizerTM) in Asthmatic Patients

By  

Respiration, Vol. 72, Iss. 1, 2005-05 ,pp. : 6-12

Karger

Access to resources Recommend Favorite

A Randomized, Double-Blind, Double-Dummy, Safety Crossover Trial Comparing Cumulative Doses up to 96 μg of Formoterol Delivered via an HFA-134a-Propelled pMDI vs. Same Cumulative Doses of Formoterol DPI and Placebo in Asthmatic Patients

By  

Respiration, Vol. 72, Iss. 1, 2005-05 ,pp. : 28-34

Karger

Access to resources Recommend Favorite

Comparable Efficacy and Tolerability of Formoterol (Foradil®) Administered via a Novel Multi-Dose Dry Powder Inhaler (Certihaler™) or the Aerolizer® Dry Powder Inhaler in Patients with Persistent Asthma

By  

Respiration, Vol. 71, Iss. 2, 2004-03 ,pp. : 126-133

Karger

Access to resources Recommend Favorite

Lobeglitazone and pioglitazone as add‐ons to metformin for patients with type 2 diabetes: a 24‐week, multicentre, randomized, double‐blind, parallel‐group, active‐controlled, phase III clinical trial with a 28‐week extension

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 6, 2015-06 ,pp. : 599-602

John Wiley & Sons Inc

Access to resources Recommend Favorite